Scorpius (NYSEMKT:SCPX) stock is taking a beating on Wednesday after the company provided details on a public offering. Scorpius has announced that it will sell 12.5 million shares of SCPX stock in this public offering. The company has also priced these shares at $1 each. That will see it generate gross proceeds of $125 million from this offering. Additionally, underwriters have a 45-day option to acquire another 1.875 million shares of SCPX stock at the offering price. This could provide the company with a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0002 par value per share SCPX NYSE American LLC Common Stock Purchase Rights NYSE American LLC FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 31, 2024 Scorpius Holdings, Inc. (Exact name of registrant as specified in charter) Delaware (Stat ...

Scorpius Holdings, Inc. Scorpius Holdings, Inc. is an integrated contract development and manufacturing organization (CDMO) focused on rapidly advancing biologic and cell therapy programs to the clinic and beyond. Scorpius offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its state-of-the-art facilities in San Antonio, Texas. With an experienced team and new, purposebuilt U.S. facilities, Scorpius is dedicated to transparen ...

Scorpius has previously initiated cGMP activities in its microbial facilities, and the commencement of mammalian cGMP campaigns marks a significant development as it opens additional revenue streams for the Company's CDMO operations. Scorpius boasts a dedicated mammalian cell culture facility with cGMPcompliant controlled cleanrooms illustrating Scorpius' commitment to providing tailored and adaptable manufacturing solutions. Scorpius Holdings Inc. is an integrated contract development and manufacturing org ...

DURHAM, N.C., July 18, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX), ("Scorpius" or the "Company"), an integrated contract development and manufacturing organization (CDMO), today announced the successful execution of its first current Good Manufacturing Practice (cGMP) microbial batches at its San Antonio manufacturing facility. This significant milestone marks the beginning of Scorpius' support for manufacturing programs through clinical manufacturing, with aspirations for future ...

DURHAM, N.C., July 18, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX), ("Scorpius" or the "Company"), an integrated contract development and manufacturing organization (CDMO), today announced the successful execution of its first current Good Manufacturing Practice (cGMP) microbial batches at its San Antonio manufacturing facility. This significant milestone marks the beginning of Scorpius' support for manufacturing programs through clinical manufacturing, with aspirations for future ...

At Scorpius Holdings, Inc's Annual Meeting of Shareholders (the "Annual Meeting") held on July 15, 2024, the Company's stockholders approved a proposal to amend the Company's certificate of incorporation to effect a reverse stock split of its Common Stock at a ratio of between 1-for-5 to 1-for-200, with the ratio within such range to be determined at the discretion of the Company's Board. Following the Annual Meeting, the Board approved a final split ratio of 1-for-200. Following the Reverse Stock Split, th ...

Forward-Looking Statement At Scorpius Holdings, Inc's Annual Meeting of Shareholders (the "Annual Meeting") held on July 15, 2024, the Company's stockholders approved a proposal to amend the Company's certificate of incorporation to effect a reverse stock split of its Common Stock at a ratio of between 1-for-5 to 1-for-200, with the ratio within such range to be determined at the discretion of the Company's Board. Following the Annual Meeting, the Board approved a final split ratio of 1-for-200. Following t ...

Financial Results - Scorpius Holdings, Inc. reported financial results for the quarter ended March 31, 2024, with a press release issued on May 29, 2024[4]. - The company has not disclosed specific financial metrics or performance indicators in the provided documents[5]. - The press release attached as Exhibit 99.1 contains detailed financial information, which is not included in the current report[5]. Stockholder Information - The 2024 Annual Meeting of Stockholders is scheduled for August 2, 2024, with a record date of June 13, 2024[7]. - Stockholder proposals for the 2024 Annual Meeting must be received by June 8, 2024, to be considered for inclusion in the proxy materials[8]. - Timely notice for director nominations or other proposals must also be delivered by June 8, 2024[9]. Company Classification and Compliance - The company is not classified as an emerging growth company under the Securities Act[3]. - The filing does not include any new or revised financial accounting standards compliance[3]. Product and Market Insights - The report does not provide any insights into new products, technologies, or market expansion strategies[5]. Company Listing - The company is listed on NYSE American LLC under the trading symbol SCPX[2].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission file number: 001-35994 Scorpius Holdings, Inc. (Exact name of registrant as specified in its c ...